<DOC>
	<DOC>NCT01786902</DOC>
	<brief_summary>Growth hormone therapy will improve the height of idiopathic short statured children. DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to non-treatment group in efficacy and safety.</brief_summary>
	<brief_title>Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Chronological Age â‰¥ 4 Bone Age &lt;11 (for girls) and &lt;13 (for boys) Height &lt;3rd percentile for age normal thyroid function endocrine and/or metabolic disorders growth failure caused by other disorders previous use of drugs that could interfere with Growth Hormone treatment</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>growth hormone</keyword>
</DOC>